ArticleTherapeutic advances in medical oncology2026
Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer.
Weifang Tang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.